Avoid unnecessary axillary surgery
For your high-risk DCIS patients. Only with Magtrace®.
Avoid unnecessary axillary surgery
For your high-risk DCIS patients. Only with Magtrace®.
Avoid unnecessary axillary surgery
For your high-risk DCIS patients.
Only with Magtrace®.
Avoid unnecessary axillary surgery
For your high-risk DCIS patients. Only with Magtrace®.
There is now a new way to avoid SLNB for high-risk DCIS patients
There is now a new way to avoid SLNB for high-risk DCIS patients
Every year, hundreds of thousands of women across the world are diagnosed with ductal carcinoma in-situ (DCIS).
The standard treatment for high-risk patients is to remove the DCIS, and at the same time perform a sentinel lymph node biopsy (SLNB).
But could less treatment be better for both patients and clinicians?
Every year, hundreds of thousands of women across the world are diagnosed with ductal carcinoma in-situ (DCIS).
The standard treatment for high-risk patients is to remove the DCIS, and at the same time perform a sentinel lymph node biopsy (SLNB).
But could less treatment be better for both patients and clinicians?
The 'delayed' sentinel
lymph node biopsy
The 'delayed' sentinel
lymph node biopsy
The 'delayed' sentinel
lymph node biopsy
The 'delayed' sentinel
lymph node biopsy
Pioneering clinical studies now show that it is possible for many high-risk DCIS patients to avoid a SLNB altogether.
The way forward involves the Magtrace® lymphatic tracer and a new technique called delayed sentinel lymph node biopsy (dSLNB), which allows you to hold off on performing axillary surgery until you know you need to.
Pioneering clinical studies now show that it is possible for many high-risk DCIS patients to avoid a SLNB altogether.
The way forward involves the Magtrace® lymphatic tracer and a new technique called delayed sentinel lymph node biopsy (dSLNB), which allows you to hold off on performing axillary surgery until you know you need to.
How does it work?
How does it work?
How does it work?
How does it work?
Magtrace® is injected into the breast prior to surgery to mark the sentinel lymph nodes. It has been designed to remain in the nodes for many weeks (unlike other tracers).
The patient will then undergo a mastectomy, with the DCIS sent for pathological analysis. SLNB is not performed at this stage.
Magtrace® is injected into the breast prior to surgery to mark the sentinel lymph nodes. It has been designed to remain in the nodes for many weeks (unlike other tracers).
The patient will then undergo a mastectomy, with the DCIS sent for pathological analysis. SLNB is not performed at this stage.
Magtrace® is injected into the breast prior to surgery to mark the sentinel lymph nodes. It has been designed to remain in the nodes for many weeks (unlike other tracers).
The patient will then undergo a mastectomy, with the DCIS sent for pathological analysis. SLNB is not performed at this stage.
Is the surgery necessary?
Is the surgery necessary?
Is the surgery necessary?
Is the surgery necessary?
If the DCIS is proven to be non-invasive, no further axillary surgery is required. Nodes are saved.
If the DCIS is invasive, the lymph nodes have remained marked and can be operated on in due course.
If the DCIS is proven to be non-invasive, no further axillary surgery is required. Nodes are saved.
If the DCIS is invasive, the lymph nodes have remained marked and can be operated on in due course.
THE CLINICAL DATA
THE CLINICAL DATA
THE CLINICAL DATA
SentiNOT –
The study that revolutionised axilla management
SentiNOT –
The study that revolutionised axilla management
SentiNOT –
The study that revolutionised axilla management
SentiNOT –
The study that revolutionised axilla management
Delayed SLNB is now routinely used around the world, but it all began with one groundbreaking study led by Dr. Andreas Karakatsanis – SentiNOT.
Delayed SLNB is now routinely used around the world, but it all began with one groundbreaking study led by Dr. Andreas Karakatsanis – SentiNOT.
Delayed SLNB is now routinely used around the world, but it all began with one groundbreaking study led by Dr. Andreas Karakatsanis – SentiNOT.
Delayed SLNB is now routinely used around the world, but it all began with one groundbreaking study led by Dr. Andreas Karakatsanis – SentiNOT.
250+
High-risk DCIS
patients
28 days
Median time from
injection to surgery
78.7%
Patients avoiding
SLNB
98.2%
Detection rate,
when returning
Karakatsanis et al (2023)
Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis...
Read the full clinical paper
Read the full clinical paper
Read the full clinical paper
Demanded
by Patients
Demanded
by Patients
Meet Jeri, a former breast cancer survivor and patient advocate who had the opportunity to avoid a SLNB.
Meet Jeri, a former breast cancer survivor and patient advocate who had the opportunity to avoid a SLNB.
Meet Jeri, a former breast cancer survivor and patient advocate who had the opportunity to avoid a SLNB.
"There was minimal discomfort. It was basically pain-free. I believe that this will be a gamechanger for surgical treatment in breast cancer."
"There was minimal discomfort. It was basically pain-free. I believe that this will be a gamechanger for surgical treatment in breast cancer."
"There was minimal discomfort. It was basically pain-free. I believe that this will be a gamechanger for surgical treatment in breast cancer."
Meet Holly, her concerns about how axillary surgery could affect her lifestyle led her to consider all options available.
Meet Holly, her concerns about how axillary surgery could affect her lifestyle led her to consider all options available.
Meet Holly, her concerns about how axillary surgery could affect her lifestyle led her to consider all options available.
"I hope other patients ask about it [Delayed SLNB] because it really is such a simple solution, and has been life-changing for me."
"I hope other patients ask about it [Delayed SLNB] because it really is such a simple solution, and has been life-changing for me."
"I hope other patients ask about it [Delayed SLNB] because it really is such a simple solution, and has been life-changing for me."
Surgical
Pioneers
Surgical
Pioneers
Surgical
Pioneers
Dr. Julie Margenthaler, MD, FACS
Dr. Julie Margenthaler, MD, FACS
St. Louis, Missouri [USA]
"Now with Magtrace, we can really do a delayed sentinel node procedure only for those who need it, and the rest of the patients can avoid the morbidity of that procedure when it's really not necessary..."
Dr. Kandace McGuire, MD
Dr. Kandace McGuire, MD
Richmond, Virginia [USA]
"...when I tell patients that they're going to get Magtrace, I tell them what the alternative would be, and why we're using one versus the other. And I think that they are very appreciative."
Mr. Ricardo Pardo-Garcia
Mr. Ricardo Pardo-Garcia
Bolton, Lancashire [UK]
"...if the result of the mastectomy comes back as [non-invasive] DCIS, we don't do anything else. So we avoid doing that sentinel lymph node biopsy in all those cases."
Dr. Emilia Dauway, MD, FACS, FRACS
Dr. Emilia Dauway, MD, FACS, FRACS
Hervey Bay, Queensland [AUS]
"...if we can eliminate that risk [of lymphedema] altogether for 80% of patients that have high risk DCIS, I think that's quite significant."
Get in touch
Get in touch
'SaveOurNodes' is a patient and physician information campaign on the 'Delayed SLNB' technique, run by Endomag (Endomagnetics Ltd).
© 2024 Endomag (Endomagnetics Ltd). All rights reserved.
'SaveOurNodes' is a patient and physician information campaign on the 'Delayed SLNB' technique, run by Endomag (Endomagnetics Ltd).
© 2024 Endomag (Endomagnetics Ltd). All rights reserved.
'SaveOurNodes' is a patient and physician information campaign on the 'Delayed SLNB' technique, run by Endomag (Endomagnetics Ltd).
© 2024 Endomag (Endomagnetics Ltd). All rights reserved.
© Endomagnetics Ltd (Endomag) is a company registered in England and Wales (No. 06227698).
Registered Office: Tower 42, 33rd Floor, 25 Old Broad Street, London EC2N 1HQ. VAT Registration No: GB 947 7709 68
© Endomagnetics Ltd (Endomag) is a company registered in England and Wales (No. 06227698).
Registered Office: Tower 42, 33rd Floor, 25 Old Broad Street, London EC2N 1HQ. VAT Registration No: GB 947 7709 68
© Endomagnetics Ltd (Endomag) is a company registered in England and Wales (No. 06227698). Registered Office: Tower 42, 33rd Floor, 25 Old Broad Street, London EC2N 1HQ. VAT Registration No: GB 947 7709 68
© Endomagnetics Ltd (Endomag) is a company registered in England and Wales (No. 06227698).
Registered Office: Tower 42, 33rd Floor, 25 Old Broad Street, London EC2N 1HQ. VAT Registration No: GB 947 7709 68